microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation

Shen, Yi; Tang, Dongfang; Yao, Ruyong; Wang, Mingzhao; Wang, Yongjie; Yao, Yasai; Li, Xiaoxiao; Zhang, Haiping
December 2013
Medical Oncology;Dec2013, Vol. 30 Issue 4, p1
Academic Journal
No abstract available.


Related Articles

  • EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. G. J. Weiss; L. T. Bemis; E. Nakajima; M. Sugita; D. K. Birks; W. A. Robinson; M. Varella-Garcia; P. A. Bunn; J. Haney; B. A. Helfrich; H. Kato; F. R. Hirsch; W. A. Franklin // Annals of Oncology;Jun2008, Vol. 19 Issue 6, p1053 

    Background: Allelic loss in chromosome 3p is one of the most frequent and earliest genetic events in lung carcinogenesis. We investigated if the loss of microRNA-128b, a microRNA located on chromosome 3p and a putative regulator of epidermal growth factor receptor (EGFR), correlated with...

  • Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations. Yokoyama, Yuhei; Sonobe, Makoto; Yamada, Tetsu; Sato, Masaaki; Menju, Toshi; Aoyama, Akihiro; Sato, Toshihiko; Chen, Fengshi; Omasa, Mitsugu; Date, Hiroshi // International Journal of Clinical Oncology;Dec2015, Vol. 20 Issue 6, p1122 

    Background: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib is an effective treatment for recurrent or advanced lung cancer harboring EGFR gene mutations, and has improved progression-free survival in several clinical trials. However, the effect of gefitinib...

  • The influence of intracellular epidermal growth factor receptor (EGFR) signal activation on the outcome of EGFR tyrosine kinase inhibitor treatment for pulmonary adenocarcinoma. KAWANO, DAIGO; YANO, TOKUJIRO; SHOJI, FUMIHIRO; ITO, KENSAKU; MORODOMI, YOSUKE; HARO, AKIRA; MIURA, NAOKO; TAKENAKA, TOMOYOSHI; YOSHINO, ICHIRO; MAEHARA, YOSHIHIKO // Surgery Today;Jun2011, Vol. 41 Issue 6, p818 

    Purpose: The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, exhibit up to a 70% response rate against non-small cell lung cancer (NSCLC) harboring somatic activating mutations of the EGFR gene ( EGFR). The mechanism of intrinsic resistance of EGFR...

  • Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non-Small-Cell Lung Cancer. Cappuzzo, Federico; Hirsch, Fred R.; Rossi, Elisa; Bartolini, Stefania; Ceresoli, Giovanni L.; Bemis, Lynne; Haney, Jerry; Witta, Samir; Danenberg, Kathleen; Domenichini, Irene; Ludovini, Vienna; Magrini, Elisabetta; Gregorc, Vanesa; Doglioni, Claudio; Sidoni, Angelo; Tonato, Maurizio; Franklin, Wilbur A.; Crino, Lucio; Bunn, Jr., Paul A.; Varella-Garcia, Marileila // JNCI: Journal of the National Cancer Institute;5/4/2005, Vol. 97 Issue 9, p643 

    Background: Gefitinib is a selective inhibitor of the epidermal growth factor (EGFR) tyrosine kinase, which is overexpressed in many cancers, including non-small-cell lung cancer (NSCLC). We carried out a clinical study to compare the relationship between EGFR gene copy number, EGFR protein...

  • Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. FR Hirsch; M Varella-Garcia; F Cappuzzo; J McCoy; L Bemis; AC Xavier; R Dziadziuszko; P Gumerlock; K Chansky; H West; AF Gazdar; L Crino; DR Gandara; WA Franklin; PA Bunn // Annals of Oncology;Apr2007, Vol. 18 Issue 4, p752 

    Background: Biological markers for optimal selection of patient to epidermal growth factor receptor (EGFR)-targeted therapies are not established in advanced non-small-cell lung cancer (NSCLC). Patients and methods: EGFR/HER2 gene copy number by FISH, EGFR protein and pAKT expression by...

  • Predicting Sensitivity of Non—Small-Cell Lung Cancer to Gefitinib: Is There a Role for P-Akt? Pao, William; Miller, Vincent A.; Venkatraman, Ennapadam; Kris, Mark G. // JNCI: Journal of the National Cancer Institute;8/4/2004, Vol. 96 Issue 15, p1117 

    Explores the role of phosphatidylinositol 3-kinase/Akt in predicting sensitivity of non-small-cell lung cancer (NSCLC) to gefitinib. Inhibition of epidermal growth factor receptor (EGFR) by gefitinib; Association of mutations in the tyrosine kinase domain of EGFR with gefitinib sensitivity in...

  • Prognostic Factors for Gefitinib-Treated Postoperative Recurrence in Non-Small Cell Lung Cancer. Okami, Jiro; Taniguchi, Kazuya; Higashiyama, Masahiko; Maeda, Jun; Oda, Kazuyuki; Orita, Naoki; Koizumi, Kyoko; Kodama, Ken; Kato, Kikuya // Oncology;2007, Vol. 72 Issue 3/4, p234 

    Background and Objectives: The association between epidermal growth factor receptor (EGFR) mutations and response to EGFR tyrosine kinase inhibitor (TKI) has been consistently confirmed in a number of studies. However, it is still unclear whether a response to TKI treatment translates into...

  • Concise Reviews of Studies Relevant to Hematology Oncology Pharmacy. Ignoffo, Robert J. // Journal of Hematology Oncology Pharmacy;Sep2016, Vol. 6 Issue 3, p108 

    BACKGROUND: The epidermal growth factor receptor (EGFR)-targeting tyrosine kinase inhibitors (TKIs) gefitinib (Iressa), erlotinib (Tarceva), and afatinib (Gilotrif) are approved by the US Food and Drug Administration for the first-line treatment of EGFR mutation– positive...

  • Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation. Cho, Su-Hee; Park, Lee; Ji, Jun; Park, Silvia; Hwang, Deok; Lee, Ji; Choi, Yoon-La; Han, Jung-Ho; Sun, Jong-Mu; Ahn, Jin; Park, Keunchil; Ahn, Myung-Ju // Cancer Chemotherapy & Pharmacology;Aug2012, Vol. 70 Issue 2, p315 

    Purpose: The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) gefitinib and erlotinib have shown dramatic response rate (RR) and significant prolongation of progression-free survival (PFS) in non-small-cell lung cancer (NSCLC) patients with EGFR mutation. Since only a few...

  • SNPs in the transforming growth factor-β pathway as predictors of outcome in advanced lung adenocarcinoma with EGFR mutations treated with gefitinib. Zhang, L.; Li, Q. X.; Wu, H. L.; Lu, X.; Yang, M.; Yu, S. Y.; Yuan, X. L. // Annals of Oncology;Aug2014, Vol. 25 Issue 8, p1584 

    The manuscript describes the original research investigating the use of genetic variations to predict response of lung adenocarcinoma to tyrosine kinase inhibitor (TKI) treatment. We found that the genetic variations in the transforming growth factor-β (TGF-β) signaling pathway are...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics